Business Context and Reporting Period
Zymeworks Inc. filed a Form 8-K dated October 18, 2022, reporting that its subsidiary, Zymeworks BC Inc., entered into a License and Collaboration Agreement with Jazz Pharmaceuticals Ireland Limited. The agreement covers the development and commercialization of zanidatamab, a bispecific HER2 antibody, in specified global territories. The filing was signed on October 19, 2022.
Key Financial and Operating Terms
- Upfront payment: Jazz agreed to pay Zymeworks a non-refundable $50.0 million after receipt of U.S. Hart-Scott-Rodino antitrust clearance.
- Additional payment: If Jazz elects to retain its licenses and rights, it must pay an additional $325.0 million after the later of HSR clearance and delivery of specified top-line and supporting data from the HERIZON-BTC-01 study. Failure to make this payment causes the agreement to terminate automatically.
- Milestones: Zymeworks is eligible for up to $525.0 million in regulatory milestones and up to $862.5 million in commercial milestones.
- Royalties: Subject to regulatory approval, Zymeworks is eligible for tiered royalties of 10% to 20% on annual net sales of Licensed Products in the territory, subject to customary reductions.
- Development reimbursement: Jazz will reimburse Zymeworks for specified development activities under an agreed development plan and budget.
- Manufacturing: Zymeworks will initially manufacture or arrange manufacturing of zanidatamab and Licensed Products for Jazz, with transition to Jazz or its contract manufacturer expected no later than three years after closing, subject to the agreement.
- The filing does not provide current-period revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet amounts.
Material Changes and Strategic Implications
- Jazz received exclusive, royalty-bearing rights to develop and commercialize zanidatamab and certain related antibodies in the defined territory, excluding China, Australia, New Zealand, numerous Asian countries, and other listed jurisdictions.
- BeiGene retains exclusive commercialization rights in the excluded countries under its prior agreement with Zymeworks.
- Jazz will be responsible for development and commercialization in its territory at its own cost, while Zymeworks remains responsible for specified ongoing clinical studies and filing the first Biologics License Application, with costs reimbursed by Jazz.
- The agreement excludes antibody-drug conjugates, including zanidatamab zovodotin, also known as ZW49.
- Zymeworks granted Jazz territorial exclusivity for the licensed products, while retaining certain rights relating to ZW49, existing platform partnerships, and specified platform activities.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The transaction remains subject to HSR clearance. The licenses and the $50.0 million payment become effective or payable following that clearance.
- The potential $325.0 million payment is contingent on Jazz’s election to retain the rights and on delivery of specified HERIZON-BTC-01 data. The agreement terminates automatically if Jazz does not make the payment within the specified period.
- Milestone payments and royalties depend on clinical development, regulatory approvals, commercial performance, patent and regulatory exclusivity, and product sales; none is assured.
- Jazz may terminate the agreement in its entirety or by region at any time upon notice. Either party may also terminate for specified uncured material breaches, insolvency, or failure to obtain HSR clearance by the applicable deadline.
- Termination may eliminate Zymeworks’ future rights to payments and licenses granted to Jazz, although certain Jazz licenses to Zymeworks survive termination and additional transition rights may apply.
- The agreement requires Jazz to use commercially reasonable efforts for development, regulatory approval, and commercialization in specified major markets, but the filing does not provide a product launch timetable or financial guidance.
Important Facts for Investors to Verify
- Whether and when HSR clearance was obtained and whether the $50.0 million upfront payment was received.
- Whether Jazz elected to retain its rights and paid the additional $325.0 million following delivery of the HERIZON-BTC-01 data.
- The status and results of HERIZON-BTC-01 and the timing of the first BLA filing and any regulatory approvals.
- The precise territory, BeiGene rights, and any subsequent amendments or termination notices.
- Future recognition, if any, of upfront and milestone payments under applicable accounting rules, as this 8-K does not provide accounting treatment or liquidity projections.
- The full redacted License and Collaboration Agreement, which the company stated would be filed as an exhibit to its 2022 Form 10-K.